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Our body responds to any infection — viral, bacterial, fungal, whatever — in ways 
that tend to restrict its spread. In 
other words, these responses tend 
to ‘quarantine’ the infection in 
‘containment zones’. This category 
of responses is what we refer to as 
inflammation. In addition, the human 
body also has responses that are 
directly antiviral.
Antiviral responses
It is useful to think about interactions 
between the human body and the 
viruses infecting it in ways that are 
more nuanced than a ‘fight’. Many a 
time, the body simply tolerates viruses. 
At other times, viruses simply ‘ride 
along’ with cells of the body rather 
than damaging them. At yet other 
times, the body’s response does not 
really ‘fight’ the virus infection.
That said, the body has three major direct 
ways of limiting a virus infection. In one 
antiviral response, the body sends signals 
to its own cells to make life difficult for 
any virus entering them. Examples of 
such signals include interferon-alpha 
and interferon-beta that are being tried 
as treatments for COVID-19. Another 
response is for the body to produce 
proteins, called antibodies, that stick 
to the exact part of the virus surface 
through which the virus sticks to body 
cells. Such antibody-coated viruses 
cannot get into cells to infect them. This 
is what treatments like plasma therapy 
or monoclonal antibody therapy hope 
to achieve. It is also what we hope to 
generate with the SARS-CoV-2 vaccines 
that are in the pipeline. A third way the 
body limits virus infection is through 
‘killer’ cells. Killer cells can identify and 
kill recently infected body cells before the 
production of new virus copies in them 




How does our body respond 
to infection? Can it limit 
infection by a virus? How 
is inflammation different 
from an adaptive response? 
What factors can weaken 
our immune response? 
What do ‘cytokine storms’ 
have to do with COVID-19? 
How do we develop herd 
immunity? 
OUR RESPONSE
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Antiviral responses involving antibodies 
and killer cells are called adaptive 
responses. They ‘look’ at the virus 
that has come in, then ‘search’ and 
‘find’ antibody-producing and killer 
cells in their own repertoires that can 
match bits on the surface of the virus 
or a virus infected cell. This part of 
the body’s repertoire of cells is then 
expanded and brought into operation, 
either as antibodies or as killer cells. The 
expanded repertoire remains in the body 
even after the virus is dealt with.
Adaptive responses
Everyone has inflammatory and 
interferon responses to viral infection. 
These responses come into operation 
immediately (within minutes to 
hours) after infection. Adaptive 
antiviral responses are perhaps more 
effective, but take a little time to kick 
in. Especially if we have no previous 
exposure to anything that looks like 
the virus (the virus itself, a very very 
similar virus, or a mimic vaccine). This 
is because it takes time (usually only a 
couple of days, but sometimes a little 
more than that) to expand the body’s 
initial repertoire of matching antibody-
producing or killer cells. On the other 
hand, if the virus enters a body that 
already has an expanded adaptive 
repertoire capable of recognising the 
virus, then adaptive responses also kick 
in quickly (within minutes to hours). This 
is why we are better protected against 
reinfection by the same virus (or by 
vaccination). Keep in mind that we are 
protected by these immune responses 
even when we meet an infection for 
the first time. It is just that having an 
expanded adaptive repertoire gives 
quicker and better protection. However, 
these expanded adaptive repertoires 
can be lost over time. If this happens, 
then we become as susceptible to that 
particular infection as we would be if 
we had never met the virus before (or 
had not been vaccinated against it).
Here is what we do not know. We do not 
know how to predict which particular 
bits of the virus the body will make the 
most antibodies against. A paradoxical 
disadvantage of having a large adaptive 
repertoire is that there will be matches 
with most parts of the virus particle. 
In other words, the adaptive response 
will make antibodies against the virus 
surface and its interior. Only those 
antibodies that stick to the specific 
patches on the virus surface through 
which the virus sticks to body cells will 
provide protection (see Fig. 1). This 
means that we can never be sure if we 
will make lots of useful antibodies or 
not. Similarly, we do not know how to 
predict how long the expanded adaptive 
repertoire against any given infection 
will last in the body. This means that for 
every new pathogen we meet, and for 
every new vaccine we want to make, 
we have to learn these two things 
afresh, through trial and error. This is 
why we are, and should be, so uncertain 
about SARS-CoV-2 and COVID-19; 
we are still learning new things about 
them. This is also why ‘designing’ and 
‘making’ vaccines against SARS-CoV-2 
is uncertain and time-consuming, why 
there are over a hundred different 
efforts going on the world over, and 
why most of them stand equal chances 
of success (or failure).
Recent findings suggest that antibody 
responses against SARS-CoV-2 may be 
modest, and may last for only a few 
weeks or months, especially in people 
without any symptoms or with only 
mild symptoms. We should keep this 
possibility in mind when we think 
about how we, as a society, are going 
to respond to the disease over the long 
term (until there are reasonably effective 
vaccines available to everyone!).
Factors affecting our 
immune response
Most of us have fairly good immune 
responses. If we did not, we would 
have had lots of other infections since 
childhood, and would most likely have 
been in and out of hospitals! In fact, 
this is what happens in the case of 
people who have been undergoing 
chemotherapy for cancer. As a side-
effect of this therapy, their immune 
responses are poor enough to make them 
more likely to have severe COVID-19 
illness. A little differently, any ongoing 
inflammation can affect containment 
and antiviral responses enough to 
increase our chances of developing severe 
COVID-19 illness. This is what happens 
in the case of the elderly, those with 
obesity, type 2 diabetes, heart disease 
or hypertension, as well as those with 
chronic kidney, liver, or lung diseases. 
Fig. 1. Antibodies offer protection when they stick to the exact part of the virus surface 
through which the virus sticks to body cells. 
Credits: Adapted from an image by Erlangen, Germany, on Siemens Healthineers. URL: https://www.
siemens-healthineers.com/en-in/press-room/press-releases/covid-19-antibody-phe.html. 
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Cytokine storms
The inflammatory immune response 
tends to provide containment of any 
incoming pathogen to the site where 
it is first encountered by the body. The 
body uses locally made chemical signals, 
called cytokines, to create ‘micro-
containment’ zones. Of course, the 
cytokines leak a bit beyond, but in such 
small amounts that they will have no 
effect outside these zones. 
This can backfire when we are exposed 
to very high doses of the virus. This is 
common in caregivers, nurses, doctors, 
and other healthcare workers with 
prolonged exposure to infected people 
(or those who spend hours in a crowded 
and closed room with air-conditioning). 
In such cases, the virus enters our 
body through many different points 
in the airways. This can also backfire 
if our early immune responses are 
somewhat off-kilter and slow to get 
off and running. This is seen in people 
undergoing chemotherapy for cancer, 
or with ongoing inflammation in the 
body. In such cases, even a small dose 
of the virus will expand and spread to a 
number of locations in the body by the 
time the immune response is activated. 
In both cases, all the immune response 
can, and will, try to do is achieve micro-
containment at all locations. The trouble 
is that cytokines will leak out from each 
of these ‘wannabe’ micro-containment 
zones. All the leaking chemicals add 
up to a lot, and begin to have effects 
outside the localised zones, all over the 
body. The result is that the entire body 
attempts to become a huge containment 
zone, like an entire country shut down 
for months in a policed ‘lockdown’. This 
accumulation of cytokines all over the 
body is referred to as a cytokine storm, 
and results in severe illness. 
Herd immunity
Let us think about how a virus spreads 
(or is ‘transmitted’) in a community. Let’s 
say one person is exposed to the virus (in 
some remote jungle, let us assume!) and 
is infected. Till they deal with the virus, 
new virus copies will get made in their 
body. If the virus is lucky (!), these copies 
will be thrown out of the body somehow 
(usually via bodily fluids). On making 
appropriate contact with other people, 
these copies can establish infection. 
So, by the time the first person to be 
infected eliminates the virus from their 
body, the next round of people will be 
making and transmitting copies of it. 
A crucial factor for the ‘success’ of the 
virus is the number of people who get 
successfully infected from one infected 
person. If this number (called ‘R’) is less 
than one, then each cycle of spread will 
be smaller than the one before it, and 
the infection will simply die down. The 
greater than one this number is, the 
more rapid the spread of the infection 
in the community. However, this number 
also depends on the immunity of people 
exposed to an infected person. People 
who have met the virus earlier, and have 
expanded their adaptive repertoire in 
response are adaptive immune. Such 
people do not get infected. If most of 
the people an infected person comes 
into contact with are adaptive immune, 
then it reduces the efficiency with which 
the virus spreads. This will also happen 
Fig. 2. Herd immunity is a natural consequence of a critical proportion of people in a 
community becoming adaptive immune to a pathogen. To start with, no one is immune 
to novel pathogens like SARS-CoV-2. The infection spreads rapidly through the 
community. Over time, two categories of people become adaptive immune to it — those 
who recover from the infection, and those who receive a vaccine against it. Research 
suggests that protection from the adaptive immune response in COVID-19 infected 
people may last for only a few weeks or months. As of now, there is no proven vaccine 
against the virus. If enough people in a community become adaptive immune to the 
pathogen, it reduces the chances of those who are less immune to it from coming into 
contact with an infected person. This reduces the spread of infection. Estimates suggest 
that this is likely to happen with SARS-CoV-2 when 50-80% of the population becomes 
adaptive immune to it. 
Credits: Tkarcher, Wikimedia Commons. URL: https://commons.wikimedia.org/wiki/File:Herd_
immunity.svg. License: CC-BY-SA. 
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if a large proportion of people become 
adaptive immune because they are 
exposed to a reasonably effective vaccine 
(rather than actually getting infected). 
So, if a large enough proportion of 
people in a community are adaptive 
immune to the virus, it is likely that the 
spread of the virus will essentially come 
to a halt (see Fig. 2). This situation is 
called herd immunity. But, perhaps, we 
should call it ‘community immunity’, 
which is both rhyming and accurate?
Parting thoughts
As we can see, most infections will, in 
all likelihood, reach the point of herd 
immunity sooner or later. So herd 
immunity is just a natural outcome, not 
a policy strategy that either Sweden 
or Mister Boris Johnson designed (and, 
of course, relying on it as a ‘strategy’ is 
quite silly in both cases).
What proportion of people must be 
adaptive immune to SARS-CoV-2 
for this point of herd immunity to 
be reached? We don’t know for sure 
— the percentage varies based on a 
number of factors specific to individual 
infections and microbes. However, 
numbers between 50-80% have been 
brought up. As of now, the highest 
recorded proportion of people with 
adaptive immunity to SARS-CoV-2 is 
about 20%. Clearly, SARS-CoV-2 herd 
immunity has not developed in any 
part of the world yet.
It will be evident that for a stable 
situation of herd immunity to 
come about, virus infection must 
result in a good protective adaptive 
immune response, and this response 
(antibodies, for example) must not 
disappear quickly. For SARS-CoV-2 
virus, while the first condition appears 
to be fulfilled in a fair proportion of 
infected people, there seems to be 
some uncertainty about how long 
antibodies last. So it is possible that 
herd immunity for SARS-CoV-2 will 
be somewhat unstable. To stabilise 
the situation, it is likely that we will 
depend (more than we had originally 
thought) on the vaccines that will 
begin to come out next year.
Note: Source of the image used in the background of the article title: https://www.flickr.com/photos/niaid/49680384281/in/photostream/. Credits: The National 
Institute of Allergy and Infectious Diseases, US. License: CC-BY.
• The human body uses inflammation and antiviral responses to protect us from a virus infection. 
• Inflammation restricts spread of infection by using cytokines to quarantine it in containment zones.
• Antiviral responses limit infection in three major ways — signalling cells to make virus entry 
difficult, producing antibodies that prevent the virus from attaching to cells, and recruiting killer 
cells to identify and kill infected cells.
• Since antiviral responses involving antibodies and killer cells are ‘adaptive’, they may take time to 
kick in.
• Antibody responses against SARS-CoV-2 may be modest, and may last for only a few weeks to months.
• People undergoing chemotherapy for cancer, and with ongoing inflammation are more prone to 
severe COVID-19 illness.
• Two factors — exposure to high doses of virus, and compromised immunity — can lead to cytokine 
storms that result in severe illness.
• Herd immunity is the natural consequence of a large number of people becoming adaptive immune 
because of prior exposure to the virus, or effective vaccination.
Satyajit Rath is currently a Visiting Professor at the Indian Institute of Science Education and Research (IISER), Pune. 
He was formerly a scientist at the National Institute of Immunology (NII), New Delhi.
Key takeaways
